ACER News and Press, Acer Therapeutics Inc. From 01/05/23

Acer Therapeutics ( NASDAQ: ACER ) is trading ~5% higher after the company began two Phase 2 investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of the prostate. The two-trials are - The POSH-MAP, which is Pilot of Osanetant for Severi...

NEWTON, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the init...

Acer Therapeutics ( NASDAQ: ACER ) said it regained compliance with Nasdaq's rule of $35M market value of listed securities requirement for continued listing on the exchange. The company added that the listing matter is now closed and the previously-scheduled hearing before the Na...

NEWTON, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that The...

Despite US FDA approval of Acer Therapeutics' ( NASDAQ: ACER ) Olpruva (sodium phenylbutyrate) for urea cycle disorders, the company's stock is down 33% in Tuesday afternoon trading. The approval triggers the availability of a $42.5M loan term agreement with affiliate...

New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn, would extend cash runway into H2 2023 NEWTON, Mass. and GENEVA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasda...

The U.S. Food and Drug Administration (FDA) has greenlighted Olpruva, being developed by Acer Therapeutics ( NASDAQ: ACER ) and Swiss biotech Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) as a treatment for patients with urea cycle disorders (UCD). The oral treatment, al...

NEWTON, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it...

Acer Therapeutics press release ( NASDAQ: ACER ): Q3 GAAP EPS of -$0.31 beats by $0.37 . Cash and cash equivalents were $6.4M as of September 30, 2022, compared to $12.7M as of December 31, 2021. Acer believes its cash and cash equivalents available as of September...

NEWTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported fi...